" class="no-js "lang="en-US"> Wheeler Bio - Pharmtech Focus
Tuesday, January 31, 2023

Breaking News

MedRhythms Feasibility Study Shows Positive Topline Results in Parkinson’s Disease Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors Bruno Ultra Barcelos is appointed Managing Director of Ethypharm UK Axion BioSystems Launches New High-Throughput Live-Cell Imaging Platform, Omni Pro 12 CHOP Experts Share Cutting-Edge Innovations at Arab Health Exhibition Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology ClariMed Launches Integrated Medical Device Services Partner
Wheeler Bio | Pharmtech Focus

Wheeler Bio

About Wheeler Bio

Wheeler Bio
A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.

Related Story

Appointments

 Wheeler Bio Announces Roger Lias

Wheeler Bio Announces Roger Lias, Ph.D. as President and Chief Operating Officer

September 23 2022

Wheeler Bio, a new contract development and manufacturing organization (CDMO) specializing in the cell line […]